B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous malignancy and consists of several genetic abnormalities. Some of these abnormalities are used in clinic for risk calculation and treatment decision. ZNF384 rearrangements are one of the new oncogenic subtypes that have been identified in BCP-ALL by recent studies. Also patients with ZNF384 fusions have been reported in with mixed phenotypic acute leukemia (MPAL). In this study, we screened 133 pediatric patients with ALL for the most common ZNF384 fusions; ZNF384-TCF3, ZNF384-EP300 and ZNF384-TAF15 by using qPCR. The total frequency of ZNF384 gene rearrangements was 8.2% in the cohort. We identified ZNF384 fusions in 9.5% of mixed phenotypic leukemia and 7.6% of BCP-ALL groups. Moreover, a novel breakpoint was identified in ZNF384-TCF3 fusion. Patients with MPAL showed significantly higher ZNF384 expression than BCP-ALL and controls. Patients with ZNF384 rearrangements had intermediate survival rates based on other subtypes.